局部晚期宫颈癌放化疗后肾积水的个体肾脏水平分析
本研究回顾性分析225例局部晚期宫颈癌患者449个肾脏,接受外照射放疗联合同期顺铂及图像引导自适应近距离放疗。新发肾积水15.8%,放疗诱发肾积水(RIH)5年累积发生率7.2%,A型RIH与同侧A点剂量相关且未随时间平台化,末次随访19.6%肾脏肾积水未缓解。
要点
- 基线肾积水占10.9%,放疗后38.8%缓解。
- 新发肾积水15.8%,肿瘤复发所致多于RIH(2:1)。
- RIH 5年累积发生率7.2%,A型RIH与同侧A点剂量相关。
核心结论
- 局部晚期宫颈癌根治性放疗后持续性肾积水并不少见(20%),RIH在5年时是相关病因(7%)。
- A型RIH(输尿管损伤)通常为单侧,与同侧A点剂量相关,且发生率不随时间平台化;B型RIH(其他结构损伤)则不同。
研究设计与样本
- 回顾性分析225例接受外照射放疗联合同期顺铂及图像引导自适应近距离放疗的局部晚期宫颈癌患者的449个肾脏。
- 在个体肾脏水平进行单因素和多因素分析,并按患者聚类。
主要发现
- 基线时10.9%(49/449)的肾脏受肾积水影响,放疗后38.8%(19/49)缓解。
- 随访期间新发肾积水见于15.8%(71/419)的肾脏,肿瘤复发所致多于RIH(比例2:1)。
- 每个肾脏的总体RIH发生率为5.7%(95% CI,3.2-8.1),3年和5年分别为7.2%(95% CI,3.8-10.4)。
- A型RIH(输尿管狭窄)3年和5年发生率分别为1.9%(95% CI,0.5-3.3)和3.5%(95% CI,0.8-6.2);B型RIH(输尿管以外结构损伤)3年和5年发生率均为3.8%(95% CI,1.7-5.9)。
- 多因素模型中,A点剂量(P = .01;EQD23)、膀胱D2.0cc(P = .03;EQD23)和高危临床靶区体积(P < .01;cm3)与总体肾积水发生率相关;A点剂量与A型RIH相关(P < .01),与B型无关(P = .74)。
关键数值与推荐
- A点剂量(EQD23)与总体肾积水发生率相关(P = .01),并与A型RIH相关(P < .01)。
- 膀胱D2.0cc(EQD23)与总体肾积水发生率相关(P = .03)。
- 高危临床靶区体积(cm3)与总体肾积水发生率相关(P < .01)。
- 末次随访时19.6%(88/449)的肾脏肾积水未缓解。
临床怎么用
- 对局部晚期宫颈癌放疗患者应关注个体肾脏肾积水发生,尤其注意A点剂量和膀胱D2.0cc等剂量参数。
- 放疗后肾积水需鉴别肿瘤复发与RIH,A型RIH与同侧A点剂量相关且不随时间平台化,需长期随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Hydronephrosis is a complex renal abnormality that requires assessment of individual-kidney status at different times for correct interpretation of the mechanism of damage. This study analyzes all hydronephrosis events in women with locally advanced cervical cancer. METHODS AND MATERIALS: The status of 449 kidneys from 225 women treated with external beam radiation therapy (RT) with concurrent cisplatin and image guided adaptive brachytherapy were retrospectively reviewed. Hydronephrosis incidence, causes (including radiation-induced hydronephrosis [RIH]), associated factors, and resolution rates were analyzed. Univariable and multivariable analyses were performed at the individual-kidney level, clustered by individual patient. RESULTS: At baseline, 10.9% (49/449) of the kidneys were affected by hydronephrosis, which resolved in 38.8% (19/49) after RT. During follow-up, new hydronephrosis occurred in 15.8% (71/419) of the kidneys, caused more frequently by cancer recurrence than by RIH (2:1 ratio). The overall RIH incidence per kidney was 5.7% (95% CI, 3.2-8.1) and 7.2% (95% CI, 3.8-10.4) at 3 and 5 years, respectively. The rates of type A RIH (ureteral stenosis) at 3 and 5 years were 1.9% (95% CI, 0.5-3.3) and 3.5% (95% CI, 0.8-6.2). Both 3- and 5-year rates of type B RIH (damage to structures other than ureter) were 3.8% (95% CI, 1.7-5.9). Point A dose (P = .01; EQD23), bladder D2.0cc (P = .03; EQD23), and high-risk clinical target volume (P < .01; cm3) were associated with overall hydronephrosis incidence in the multivariable model. Point A dose was associated with type A RIH (P < .01) but not with type B (P = .74). At last follow-up, 19.6% (88/449) of kidneys had unresolved hydronephrosis. CONCLUSIONS: Persistent hydronephrosis is not uncommon after definitive RT for locally advanced cervical cancer (20%), with RIH being a relevant etiology at 5 years (7%). In contrary to type B RIH (damage to other structures), type A (ureteral damage) is usually unilateral, associated with dose to the ipsilateral point A, and its incidence does not plateau over time.
引用
- Sapienza LG, Chapman CH, Jhavar S, et al. Understanding Hydronephrosis Occurrence by an Individual-Kidney Level Analysis of all Events Postchemoradiation Therapy for Locally Advanced Cervical Cancer. Int J Radiat Oncol Biol Phys. 2025. PMID: 40348198. doi:10.1016/j.ijrobp.2025.04.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。